Generated by AI
Oragenics Inc. is a biotechnology company that focuses on the development and commercialization of pharmaceutical products for oral health and infectious diseases. The company is engaged in the creation of novel therapies utilizing its proprietary biological platform technologies. A key area of its research is aimed at the development of antibiotics to combat resistant strains of bacteria, often addressing public health challenges that require innovative solutions. Oragenics primarily targets sectors that include pharmaceuticals, healthcare, and biotherapeutics, impacting both consumer and clinical markets. The company is headquartered in Tampa, Florida, and continues to play a significant role in pioneering research within its niche, contributing to advancements in medical science and therapeutic options. By leveraging cutting-edge research in microbiomics, Oragenics is not only integral to addressing significant health concerns but also a notable contributor to the broader biotechnology and pharmaceutical industries.
Website9015 Town Center Parkway
Lakewood Ranch, FL, 34202
United States
The latest articles about OGEN.
Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the Successful Case Studies session at the IPAC-RS 2026 Nasal Innovation Forum on Thursday, September 17, 2026Presentation is expected to address development and clinical translation of ONP-002, including the intranasal delivery platform, Phase IIa trial design, and anticipated path to U.S. clinical develo
Detailed price information for Oragenics Inc (OGEN-A) from The Globe and Mail including charting and trades.
Summary of Nov 14's posts. Generated by AI.
Summary of Jan 22's posts. Generated by AI.
Summary of Jul 16's posts. Generated by AI.
Summary of Nov 12's posts. Generated by AI.
Investors talking about OGEN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.